Impact BioMedical, Inc. Total Liabilities

Latest as of September 2025: $27.06 Million USD

Impact BioMedical, Inc. total liabilities. Based on the latest financial reports, Impact BioMedical, Inc. (IBO) has total liabilities worth $27.06 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See IBO defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Impact BioMedical, Inc. (2016–2024)

Total liabilities of Impact BioMedical, Inc. from 2016 to 2024. This chart illustrates how Impact BioMedical, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Impact BioMedical, Inc. to evaluate the company's liquid asset resilience ratio.

Impact BioMedical, Inc. Competitors by Total Liabilities

The table below lists competitors of Impact BioMedical, Inc. ranked by their total liabilities.

Company Country Total Liabilities
RoboRobo Co. Ltd
KQ:215100
Korea ₩2.10 Billion
InkTec Co. Ltd
KQ:049550
Korea ₩79.82 Billion
I-Hwa Industrial Co Ltd
TW:1456
Taiwan NT$11.68 Billion
Chosun Welding
KO:120030
Korea ₩11.60 Billion
Forum Markets, Incorporated
NASDAQ:FRMM
USA $31.23 Million
Aureus Greenway Holdings Inc.
NASDAQ:PUSA
USA $1.54 Million
Public Packages Holdings Bhd
KLSE:8273
Malaysia RM34.36 Million
Enwell Energy plc
F:RHN
Germany €18.84 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Impact BioMedical, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Impact BioMedical, Inc. (IBO) total assets.

Liquidity & Leverage Metrics

Impact BioMedical, Inc. Total Liabilities Ratios Explained

Impact BioMedical, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.04 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.00 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.29 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.49 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Impact BioMedical, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Impact BioMedical, Inc. (2016–2024)

The table below shows the annual total liabilities of Impact BioMedical, Inc. from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 $13.05 Million -20.27%
2023-12-31 $16.37 Million +18.39%
2022-12-31 $13.83 Million +1219.63%
2021-12-31 $1.05 Million +1242.96%
2020-12-31 $78.03K +259.17%
2019-12-31 $21.72K +8.12%
2018-12-31 $20.09K -21.01%
2017-12-31 $25.44K +354.23%
2016-12-31 $5.60K --

About Impact BioMedical, Inc.

NYSE MKT:IBO USA Biotechnology
Market Cap
$45.54 Million
Market Cap Rank
#22080 Global
#4917 in USA
Share Price
$0.44
Change (1 day)
+0.07%
52-Week Range
$0.42 - $0.45
All Time High
$388.50
About

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more